While AI can accelerate the ideation phase of drug discovery, the primary bottleneck remains the slow, expensive, and human-dependent clinical trial process. We are already "drowning in good ideas," so generating more with AI doesn't solve the fundamental constraint of testing them.

Contrary to the belief of those outside manufacturing, establishing a bioprocess is not a one-time task. The inherent unpredictability of biology means things will inevitably go wrong even in the most controlled environments, making it a continuous and difficult challenge.

The manufacturing process fundamentally alters a cell therapy's properties. This creates a conundrum: starting with expensive, fully-automated systems is often unfeasible for early trials, but switching to automation later is risky. The high burden of proving the new process yields an equivalent product can stall late-stage development.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.

While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.

Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.

Contrary to popular belief, AI's role in drug discovery is marginal. Martin Shkreli argues the main hurdle is the billion-dollar, multi-year process of human clinical trials, an area where AI has little impact. The chemistry itself is a relatively solvable problem for experts.

The primary reason most pharmaceutical AI projects fail to deliver value is not technical limitation but strategic failure. Organizations become obsessed with optimizing algorithms while neglecting the foundational blueprint that connects AI investment to measurable business outcomes and operational readiness.